SCHEMBL16203293

SCHEMBL16203293

CC(CN=[N+]=[N-])CN=[N+]=[N-]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19344264 0.87 — —
SCHEMBL18011115 0.86 — —
SCHEMBL15133314 0.86 — —
SCHEMBL18633958 0.84 — —
SCHEMBL18709256 0.84 — —
SCHEMBL23404472 0.84 — —
SCHEMBL19480802 0.84 — —
SCHEMBL21806635 0.82 — —
SCHEMBL16926676 0.80 — —
SCHEMBL30176795 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 — — EP disclosed
US-20140323538-A1 ANTICANCER P21-ACTIVATED KINASE INHIBITORS OHIO STATE INNOVATION FOUNDATION (US) 2014-10-30 — — US disclosed
Send feedback